Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 51

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 51
---
 developments, including as a result of the change in U.S. presidential 
 administration, affecting Enfusion’s or Clearwater’s business;                                              |

| • |     | general economic and market developments and conditions; |

| • |     | the legal, regulatory and tax regimes under which Enfusion or Clearwater operates; |

29

| • |     | potential business uncertainty, including changes to existing business relationships, during the pendency of the 
 Transactions that could affect Enfusion’s or Clearwater’s financial performance;                                 |

| • |     | the risk that any announcements relating to the Transactions could have adverse effects on the market price of 
 Enfusion Common Stock or Clearwater Common Stock;                                                              |

| • |     | restrictions during the pendency of the Transactions that may impact Enfusion’s or Clearwater’s ability 
 to pursue certain business opportunities or strategic transactions;                                     |

| • |     | Clearwater’s ability to successfully integrate Enfusion’s operations into Clearwater’s business; |

| • |     | unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or 
 outbreak of war or hostilities;                                                                           |

| • |     | the finalization and audit of Enfusion’s 2024 fiscal year financial results which could potentially result 
 in changes or adjustments to the preliminary financial results previously presented; and                   |

| • |     | Enfusion’s or Clearwater’s response to any of the aforementioned factors. |

Clearwater and Enfusion caution that the foregoing list of factors is not exhaustive. Additional information concerning these and other risk factors is contained in Clearwater’s and Enfusion’s most recently filed Annual Reports on Form 10-Kand subsequently filed Quarterly Reports on Form 10-Q,Current Reports on Form 8-Kand other SEC filings, as such filings may be amended from time to time. All of the forward-looking statements made by Clearwater or Enfusion contained or incorporated by reference in this Proxy Statement/Prospectus and all subsequent written and oral forward-looking statements concerning Clearwater, Enfusion, the Transactions or other matters attributable to Clearwater or Enfusion or any person acting on either of their behalf are expressly qualified in their entirety by the cautionary statement above. Readers are cautioned not to place undue reliance on forward-looking statements contained in this Proxy Statement/Prospectus, which speak only as of the date such statements were made. Neither Clearwater nor Enfusion undertakes any obligation to update or revise any of these forward-looking statements to reflect events or circumstances that may